SAN CARLOS, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Nuvelo, Inc. today announced that it will hold a conference call to discuss its third quarter 2007 financial results and accomplishments on Thursday, November 1, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
To participate in the conference call, please dial 888-680-0894 for domestic callers and 617-213-4860 for international callers and reference conference passcode 12660108. A telephone replay of the conference call will be available through Thursday, November 15, 2007. To access the replay, please dial 888-286-8010 for domestic callers and 617-801-6888 for international callers and reference conference passcode 37585014.
Pre-registration is available but not mandatory for this conference call. Pre-registering will provide you immediate entry into the call and will facilitate the timely start of the call. You may pre-register at any time, including up to and after the call start time. Please use the following link to pre-register and view important information about this conference call: https://www.theconferencingservice.com/prereg/key.process?key=PFGKBE3WX
In addition, this call is being webcast by Thomson/CCBN and can be accessed via Nuvelo’s website at www.nuvelo.com. The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at www.earnings.com, Thomson’s individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (www.streetevents.com), a password-protected event management site.
About Nuvelo
Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo’s development pipeline includes alfimeprase, a direct-acting fibrinolytic for the treatment of thrombotic- related disorders including acute ischemic stroke and catheter occlusion and preclinical candidates NU206 for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease and NU172, a direct thrombin inhibitor for use as a short-acting anticoagulant during medical or surgical procedures. In addition, Nuvelo expects to leverage its expertise in cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities.
www.nuvelo.comdbertrand@wcpglobal.com
CONTACT: Danielle Bertrand of WeissComm Partners, Inc., +1-415-946-1056,
dbertrand@wcpglobal.com, for Nuvelo, Inc.
Web site: http://www.nuvelo.com/
http://www.streetevents.com/
http://www.earnings.com/
